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Alzheimer’s disease (AD) is a chronic progressive neurodegenerative disease. Its
mechanism is still not clear. Majority of research focused on the central nervous
system (CNS) changes, while few studies emphasize on peripheral immune system
modulation. Our study aimed to investigate the regulation of the peripheral immune
system and its relationship to the severity of the disease after treatment in an AD
model of APPswe/PSEN1dE9 transgenic (APP/PS1 Tg) mice. APP/PS1 Tg mice
(8 months old) were treated with the ROCK-II inhibitor 1-(5-isoquinolinesulfonyl)homo-piperazine (Fasudil) (intraperitoneal (i.p.) injections, 25 mg/kg/day), bone marrow
stromal cells (BMSCs; caudal vein injections, 1 × 106 BMSCs /time/mouse), Fasudil
combined with BMSCs, or saline (i.p., control) for 2 months. Morris water maze
(MWM) test was used to evaluate learning and memory. The mononuclear cells
(MNCs) of spleens of APP/PS1 Tg mice were analyzed using flow cytometry
for CD4+ T-cells, macrophages, and the pro-inflammatory and anti-inflammatory
molecules of the macrophages. Immunohistochemical staining was used to examine
the expression of ROCK-II in the spleens of APP/PS1 Tg mice. The MWM test
showed improved spatial learning ability in APP/PS1 Tg mice treated with Fasudil
or BMSCs alone or in combination, compared to untreated APP/PS1 Tg mice.
Fasudil combined with BMSCs intervention significantly promoted the proliferation of
CD4+/CD25+ and CD4+/ IL-10 lymphocytes, induced the release of cytokine factors,
and regulated the balance of the immune system to work functionally. It also shifted
M1 (MHC-II, CD86) to M2 (IL-10, CD206) phenotype of macrophages of CD11b
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and significantly enhanced the anti-inflammatory and phagocytic abilities (CD16/32) of
macrophages of CD11b. Immunohistochemical staining showed significantly decreased
expression of ROCK-II in mice treated with combination of Fasudil with BMSCs as
compared to saline control. Fasudil in combination of BMSCs improved cognition
of APP/PS1 Tg mice through the regulation of the peripheral immune system,
including reduction of ROCK-II expression and increased proportion of anti-inflammatory
M2 mononuclear phenotype and phagocytic macrophages in the spleen of the peripheral
immune system. The latter was achieved through the communication between brain and
spleen to improve the immunoregulation of CNS and AD disease conditions.
Keywords: Alzheimer’s disease, BMSCs, Fasudil, peripheralral immune system, cognition

INTRODUCTION

may be involved in future therapeutic and preventive strategies
for neuroinflammatory and neurodegenerative diseases
(Song and Suk, 2017). Human bone marrow stromal/stem
cells (BMSCs) have been reported as immunomodulatory
functions (Wada et al., 2011). Eftekharzadeh et al. (2015) has
demonstrated that BMSCs injections in the rat AD model
decrease neurotoxicity of Aβ, indicating that BMSCs could
be a potential therapy for AD (Wu et al., 2007). These lines
of evidence have offered us a new treatment strategic plan
that Fasudil and BMSCs might be promising agents for the
prevention and treatment of inflammation-related diseases, such
as AD. Since Fasudil and BMSCs have been demonstrated to
regulate the immune system, we hypothesized that combination
of both have better treatment efficacy in the mouse model of AD.
AD was described for the first time by Alois Alzheimer in 1906
(Mietelska-Porowska and Wojda, 2017), but the mechanisms of
AD pathogenesis and progression have not been elucidated to
date. It has been shown that regulatory T-cells (Tregs) exert an
impact on cognitive function (Baek et al., 2016) via decreased Aβ
deposition. Depletion of Tregs accelerates the onset of cognitive
deficit and increases Aβ deposition. It is well known that IL-10
modulates immune responses in AD patients (Torres et al., 2013)
and TGF-β signaling in T-cells to mandates the induction of
immune tolerance (Baas et al., 2016). Hence, neurodegeneration
in AD may be contributed by peripheral immune responses
(Sil et al., 2016). However, little is known about the changes
in the spleen and the association with the peripheral immune
system that might contribute to AD pathology (Subramanian
et al., 2010). Therefore, present study was aimed to explore
the pathology of AD under the influence of peripheral immune
system. We used APP/PS1 Tg mice as a model of AD and
examined the effects of Fasudil, BMSCs, or the combination
of both on cognition, the peripheral immune system, and
inflammatory responses. We observed that the combination of
Fasudil with BMSCs enhanced memory, activated the peripheral
immune reactions, and produced anti-inflammatory effects in
AD mice.

More than 47 million people worldwide suffer from Alzheimer’s
disease (AD) and this number will be increased to 131 million by
2050 (Prince et al., 2016). AD is a progressive neurodegenerative
disease, pathologically characterized by amyloid-β (Aβ) peptide
plaques and tau protein neurofibrillary tangles. It starts from
the hippocampus of the brain, which is an anatomical site
for the formation of initial memory. The plaques and tangles
from these two proteins destroy neuronal cells of the brain
and eventually impair the patient’s memories. Gradually, AD
patients lose the ability to control directional leading, causing
profound confusion. The mechanisms of the AD process are
largely unknown. AD primarily affects the central nervous
system (CNS). However, communications between the CNS
and peripheral immune system can play an important role in
AD. We believe that the mechanism of AD involves immunity
dysfunction. There are limited studies on the role of peripheral
immune system in AD. Therefore, it was of interest and
importance to investigate how the peripheral immune system
contributes to the development of AD (Subramanian et al., 2010).
APP/PS1 transgenic (APP/PS1 Tg) mice are widely used in
AD studies. APP/PS1 Tg mice start to exhibit impairment of
learning and memory at the age of 8 months (Li et al., 2016) and
significant plaques in the hippocampus at 9 months (Jankowsky
et al., 2004).
Rho-associated protein kinase (ROCK) has been
considered as a promising drug target for the prevention of
neurodegenerative and neurological diseases (Mueller et al.,
2005). ROCK-II plays an important role in majority of nervous
diseases, such as multiple sclerosis (MS), spinal cord injury,
stroke and AD. We have already shown in our previous studies
that 1-(5-isoquinolinesulfonyl)-homo-piperazine (Fasudil), a
selective ROCK inhibitor (Xin et al., 2015) decreases expression
of ROCK-II in the spleens of experimental autoimmune
encephalomyelitis (EAE) C57/BL6 mice (Yu et al., 2010). We
also demonstrated that Fasudil limits leukocyte activation and
infiltration in several models of inflammation, such as EAE or
Parkinson’s disease (PD; Hou et al., 2012; Zhao et al., 2015).
In addition, Fasudil protects neurons and mobilizes neural
stem cells in mice through conversion of pro-inflammatory
M1 macrophage to anti-inflammatory M2 cells type. Its
modulation of microglial polarization toward the M2 phenotype
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All experiments were performed in compliance with the
guidelines and regulations of Administration Office of
the International Council for Laboratory Animal Science.
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FIGURE 1 | 1-(5-isoquinolinesulfonyl)-homo-piperazine (Fasudil) or Fasudil combined with bone marrow stromal cells (BMSCs) improved spatial learning of
APPswe/PSEN1dE9 transgenic (APP/PS1 Tg) mice. Mice (8 months old) were intraperitoneally injected with 0.9% saline (NS, n = 9), Fasudil (n = 8), BMSCs (n = 10,
tail vein injection), or Fasudil combined with BMSCs (n = 10) for 2 months. (A) The schematic diagram of the Morris water maze (MWM) test and tracing of
movement locus map of each group. (B) The corresponding parameters: Latency to Target, Latency 1st Entrance to southwest (SW) zone, Mean Distance to Target,
Time in SW (%), and Distance in SW (%), were recorded in the retention test session, representing the time and distance spent by animals from the starting point
onto the platform or SW zone. Global activity in SW (%) represents the movement capabilities of each group in SW zone. Data presented are means ± SEM;
∗
p < 0.05, ∗∗ p < 0.01 as compared to saline (NS).

cycle (25 ± 2◦ C, humidity 50 ± 5%). APP/PS1 Tg mice were
screened based on the normal physiological behavior and
randomly divided into four treatment groups: (1) Normal
control mice (NS; n = 9), which were administered normal saline
(volume was adjusted similar to Fasudil treatment, i.p., 8 weeks);
(2) Fasudil-treated (F, n = 8) mice, which received daily i.p.
injection of Fasudil (Tianjin Chase Sun Pharmaceutical Co.,
Ltd.), 25 mg/kg/day, 8 weeks; (3) BMSCs (National Engineering
Laboratory for Resource Developing of Endangered Chinese
Crude Drugs in Northwest of China, Shanxi Normal University)
treated (BM, n = 10) mice, which were administered BMSCs
(1 × 106 BMSCs per mice) in the caudal vein (intravenous, i.v.),

The experimental protocols were approved by the animal Ethics
Committee of Datong University, Shanxi, China. Animals had
access to standard food and water ad libitum.

Animals and Drug Treatment
Male APPswe/PSEN1dE9 transgenic (APP/PS1 Tg) mice
(8 months old), expressing human amyloid precursor protein
(HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9),
were purchased from Model Animal Research Center of Nanjing
University (Nanjing, China). All animals were housed in
pathogen-free animal house facility at the Institute of Brain
Science, Datong University and maintained 12/12 light/dark
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were cultured in Neurobasal-A-Medium (Gibco) supplemented
with 2% B27 (Gibco), 0.1% Beta-Thiolhistidine (Gibco),
100 U/ml Penicillin and 100 µg/ml Streptomycin, 1% MEM
Non-Essential Amino Acids Solution (Gibco), 1% Sodium
Pyruvate 100 mM Solution (Gibco), 1% L-Glutamine (Gibco),
and Epidermal Growth Factor/Fibroblast Growth Factor. All
cells were cultured in an incubator (5% CO2 at 37◦ C). Small
neurospheres were observed when BMSCs were cultured to
the 5th–10th passages. Neurospheres were gently dissociated to
single BMSCs by accutase in our experiments. BMSCs were
suspended at 1 × 106 cells in 500 µl of normal saline before
injecting into the mouse by tail vein every time.

Mouse Behavior Tests
The Morris water maze (MWM) test was performed to assess
spatial learning and memory ability 2 weeks after the last
treatment using a gray plastic round pool (90 cm in diameter).
The pool was filled with opaque water maintained at constant
temperature (25 + 2◦ C) and permanent visual cues on the
walls of pool with quiet environment and consistent lighting,
as previously described (Yu et al., 2017). The MWM was
conceptually divided into four quadrants: Northeast (NE),
Northwest (NW), Southeast (SE), and Southwest (SW); and
eight zones: the Border NW zone, Internal NW zone, Border
NE zone, Internal NE zone, Border SW zone, Internal SW
zone, Border SE zone, Internal SE zone. In the center of the
target quadrant (Internal SW zone), there was a 5.0 × 5.0 cm
transparent platform hidden 2.0 cm under the water surface.
During the 5-day acquisition training, mice were individually
trained to locate the hidden platform from the starting point
for two trials/day with the cutoff time at 60 s. Mice were
guided to the platform and allowed to stay on the platform
for 10 s if it did not find the platform at 60 s. The probe
trial was performed on day 7 after the last training trial,
during which the platform was removed and mice was allowed
to swim freely for 60 s. The position of mice was tracked
by a camera above the center of the pool. The camera was
connected to an automated video acquisition and analysis
system (SMART V3.0 system, Panlab, Barcelona, Spain). Several
parameters such as latency to the target (SW) zone, latency
of the 1st entrance to the SW zone, mean distance to and
time in the SW zone (%), distance traveled in the SW zone
(%), and global activity in the SW zone (%) were used for
analysis using the SMART V3.0 system. These targets were
used to indicate the degree of memory consolidation after
training.

FIGURE 2 | Expression of ROCK II by immunohistochemical staining in the
spleens of APP/PS1 Tg mice. Mice were treated with saline (NS), Fasudil,
BMSCs, or Fasudil + BMSCs. (A–C) The double staining with ROCK II (green)
and DAPI (blue) in the spleens of APP/PS1 mice injected with 0.9% saline
(×10). (D–F) expression of ROCK II inhibited by Fasudil as compared with NS
(×10). (G–I) expression of ROCK II not significantly inhibited by intravenous
injections of BMSCs as compared with NS (×10). (J–L) expression of ROCK II
significantly inhibited by Fasudil combined with intravenous injections of
BMSCs, compared with NS treated mice (×10). Data shown are
means ± SEM. ∗ p < 0.05, ∗∗∗ p < 0.001 as compared with saline (NS).

once every 2 weeks for 8 weeks; and (4) combination therapy
group, i.e., Fasudil with BMSCs treatment (FBM, n = 10), which
received Fasudil and BMSCs at the similar dose and duration
for 8 weeks. The dose of Fasudil and BMSCs was selected based
on our preliminary experiments and clinical dosage (Yang et al.,
2010; Gu and Zhang, 2017; Yu et al., 2017).

Preparation Mononuclear Cells (MNCs) of
Spleen

Cultures of Bone Marrow Stromal Cells
(BMSCs)

Mice were sacrificed after completion of the MWM test. Spleens
were isolated under aseptic conditions and suspensions of splenic
mononuclear cells (MNCs) were prepared by grinding the
spleens through a 40 mm nylon mesh in pre-cooled DMEM.
Subsequently, red blood cells (RBC) in the suspensions were
osmotically lysed. MNCs were washed three times with PBS
before resuspending in DMEM with 10% fetal bovine serum.

BMSCs were isolated and cultured as previously reported (Yu
et al., 2017) and described by Jackson Laboratory and National
Engineering Laboratory for Resource Developing of Endangered
Chinese Crude Drugs in NW of China. Whole bone marrow
(BM) was harvested from the femur of female C57BL/6 mice
(8–12 weeks old) for BMSCs generation. After isolation, BMSCs
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FIGURE 3 | Fasudil, BMSCs, Fasudil combined with BMSCs affected CD4+T-cell proliferation and induced regulatory T cells in vitro. Splenic mononuclear cells
(MNCs) isolated from APP/PS1 Tg mice were double stained with anti-CD4, anti-CD25, anti-IL-10, anti-TGF-β and anti-IFN-γ antibodies, respectively. An aliquot of
10,000 cells was analyzed using BD flow cytometry. Cells were calculated by quadrant dot plot. Results are expressed as the percentage of double-positive cells.
Data were analyzed using two-way analysis of variance (ANOVA) with multiple comparison post hoc tests (Bonferroni). Data shown are means ± SEM. ∗ p < 0.05,
∗∗
p < 0.01, ∗∗∗ p < 0.001 as compared with saline (NS).

Flow Cytometry Analysis

30 min, which was used to identify the nuclei. Specificity of DAPI
staining was tested by incubating the spleen sections without the
primary antibodies. After the immunohistochemistry staining,
the spleen sections were covered with 5% glycerol, and examined
under a Spinning Disk Confocal Microscope (Cell Observer SD,
Carl Zeiss) for immune fluorescence.

Splenic MNCs were adjusted to 3 × 106 /ml and divided into
two parts. For cell surface staining, the MNCs were stained
for 20 min at RT in 1% BSA-PBS buffer with the following
panel of antibodies: FITC-CD4, FITC-CD11b, PE-CD25, PECD206, PE-CD86 and PE-CD16/32 (eBioscience, San Diego, CA,
USA; 1:1000). For intracellular staining, MNCs were stained for
20 min at RT in 0.3% saponin/1% BSA-PBS buffer with the
following panel of antibodies: PE-IL-10, PE-TGF-β, PE-IFN-γ
and PE-MHC-II (eBioscience; 1:1000). MNCs were gated using
forward and sideward scatter characteristics for lymphocytes and
monocytes and at least 10,000 gated events were collected using
flow cytometer (BD Biosciences, San Jose, CA, USA). Data were
analyzed using the CellQuest software.

Statistical Analysis
Graphpad Prism 5.0 (Graphpad software, San Diego, CA, USA)
was used for statistical analysis. All data were expressed as
means ± SEM. Differences between multiple groups were
evaluated by the Kruskal-Wallis one-way analysis of variance.
Data in the experiments with two groups were tested for
statistical significance by using unpaired, two-tailed Student’s
t-tests. Differences were considered significant if p ≤ 0.05.

Immunohistochemical Staining
Mice were anesthetized and transcardially perfused with PBS
followed by 4% buffered paraformaldehyde. A part of the spleens
was removed and frozen in liquid nitrogen. Cryostat sections
of the spleens were cut at 40 µm and fixed in acetone for
10 min. For immunohistochemical analysis, nonspecific binding
sites were blocked with 2% horse serum (Serotec, Bicester, United
Kingdom), and permeabilized with 0.3% Triton in 1% BSA-0.1 M
PBS for 60 min. Subsequently, spleen sections were incubated
overnight with primary anti-mouse ROCK-II antibody (1:800,
BD Bioscience) and 0.1% Triton in 1% BSA-0.1 M PBS. After
washing with PBS, reactivity was detected with Alexa Fluor 488
anti-rabbit (1:1000; Molecular Probes Invitrogen, Carlsbad, CA,
USA), followed by DAPI (1:1000, Thermo Fisher Scientific) for
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RESULTS
Fasudil Combined With BMSCs
Ameliorated Memory Deficits in
APP/PS1 Tg Mice
The MWM test is a commonly used behavioral task for evaluating
cognitive deficits (Yu et al., 2017). Efficacy of Fasudil, BMSCs,
or Fasudil combined with BMSCs was determined using the
MWM test in APP/PS1 Tg mice, which were screened for
cognitive impairment (appreciable symptoms) at the age of
8 months and 2 weeks after the last treatment (Figure 1A).
Global Activity in SW (%) reflects the body functions of
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FIGURE 4 | Fasudil or Fasudil combined with BMSCs shifted M1 macrophages to M2 phenotype of CD11b and enhanced the phagocytic ability of CD11b in vitro.
Splenic MNCs isolated from APP/PS1 Tg mice were stained with macrophage markers for M2 (CD11b+/ IL-10+, CD11b+/ CD206+) or M1 (CD11b+/ MHC-II+,
CD11b+/ CD86+), and phagocytic macrophage markers (CD11b+/CD16/32+), and an aliquot of 10,000 cells was analyzed using BD flow cytometry. A part of cells
was initially gated on forward and side scatter to remove debris and calculated by quadrant dot plot. Results are expressed as the percentage of double positive
cells and shown as means + SEM in each group from a single experiment representative of two independent experiments with similar results. Differences were
analyzed using two-way ANOVA with multiple comparison post hoc tests (Bonferroni). ∗ p < 0.05, ∗∗∗ p < 0.001 as compared with saline (NS).

the animal in order to exclude the body dysfunction for
swimming. There were no significant differences at baseline
among the groups. Latency to the target zone, first-entrance
latency to SW, mean distance to the target zone, time in
SW, and distance swam in the SW (%) zone were recorded
in the retention test session, representing the time taken and
distance traveled by animals from the starting point to the
platform or SW zone. In the APP/PS1 Tg+Fasudil group,
mice showed significantly decreased latency and first-entrance
latency to the target zone as compared with APP/PS1 Tg+Saline
mice (p < 0.05). The APP/PS1 Tg+BMSCs mice did not
exhibit statistically significant changes as compared with
APP/PS1 Tg+Saline mice in cognitive function. However,
the APP/PS1 Tg+Fasudil+BMSCs mice showed significantly
decreased latency (p < 0.05), first-entrance latency (p < 0.05),
mean distance traveled to the target zone (p < 0.01), and
increased time spent (p < 0.05) and distance traveled (p < 0.05)
in the SW zone as compared with APP/PS1 Tg+Saline mice
(Figure 1B). Our results demonstrated that Fasudil or Fasudil
combined with BMSCs improved spatial learning of APP/PS1 Tg
mice, the latter of which appeared to be more effective than
Fasudil or BMSCs alone.

Frontiers in Aging Neuroscience | www.frontiersin.org

Fasudil Combined With BMSCs Attenuated
ROCK-II Expression in the Spleens of
APP/PS1 Tg Mice
ROCK is expressed both centrally and peripherally. A plethora
of studies have demonstrated the role of Rho/ROCK pathway
in AD. This pathway is directly involved in the neuronal loss
and inhibition of axonal regeneration in AD (Wen et al.,
2014). ROCK-II is an important pharmacological target linked
to CNS disorders such as AD (Cai et al., 2017). In order to
test our hypothesis that expression of ROCK-II was altered by
treatments in the peripheral immune system of AD models,
we performed immunohistochemical staining in spleens of
APP/PS1 Tg mice. As shown in Figure 2, expression of ROCK-II
in spleens of APP/PS1 Tg mice was changed by the treatments.
More specifically, the double staining of ROCK-II (green)
and DAPI (blue) was performed in spleens of APP/PS1 mice
treated with 0.9% NS, Fasudil, BMSCs, or Fasudil combined
with BMSCs (×10). The expression of ROCK-II was inhibited
in APP/PS1 Tg+Fasudil (p < 0.001; Figures 2D–F), but
not in APP/PS1 Tg+BMSCs mice (p < 0.05; Figures 2G–I),
as compared with APP/PS1 Tg+NS (Figures 2A–C). In
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assessed by flow cytometry. All the treated groups were
compared with NS (Figure 4). Fasudil, BMSCs, and Fasudil
combined with BMSCs significantly increased expression of
CD16/32 on CD11b+/CD16/32+ macrophages (p < 0.001);
combination of Fasudil and BMSCs was more effective than
either treatment alone based on the results of expression of
the phagocytic macrophage marker. In the double staining of
CD11b+/IL-10+, Fasudil significantly decreased expression
of IL-10 (p < 0.05), while BMSCs significantly increased
expression of IL-10 on CD11b+/IL-10+ macrophages (p < 0.05);
Fasudil combined BMSCs further increased expression of
IL-10 on CD11b+/IL-10+ macrophages (p < 0.001). In the
double staining of CD11b+/CD206+, Fasudil significantly
increased the expression of CD206 on CD11b+/CD206+
macrophages (p < 0.001). BMSCs and Fasudil combined with
BMSCs also significantly increased the expression of CD206 on
CD11b+/CD206+ macrophages (p < 0.05). In contrast, in the
double staining of CD11b+/MHC-II+ and CD11b+/CD86+,
there were no significant changes in the expression of MHC-II
or CD86 between the treatment group of Fasudil, BMSCs,
or Fasudil combined with BMSCs and the NS control. The
expression of macrophage M1 markers was not significantly
affected by the treatments, but the combination of Fasudil and
BMSCs significantly increased the expression of macrophage
M2 markers. The results suggest that Fasudil or Fasudil
combined with BMSCs shifts M1 (MHC-II, CD86) to M2 (IL-10,
CD206) phenotype of CD11b, significantly enhancing the
anti-inflammatory and phagocytic ability (CD16/32) of CD11b
macrophages.

addition, the expression of ROCK-II was significantly inhibited
in APP/PS1 Tg+Fasudil+BMSCs (p < 0.001; Figures 2J–L)
as compared with APP/PS1 Tg+NS, APP/PS1 Tg+Fasudil
(p < 0.001), or APP/PS1 Tg+BMSCs (p < 0.05). Fasudil
as an inhibitor of ROCK-II can reduce the expression of
ROCK-II in the spleens of APP/PS1 Tg mice; in contrast,
BMSCs is not an inhibitor of ROCK-II, thus it potentiated
the inhibitory effect of Fasudil on expression of ROCK-II
through the immunoregulatory response. Our results suggest an
alternative approach for treatment of AD using Fasudil or Fasudil
combined with BMSCs through regulation of the peripheral
immune system and inhibition of the progression of the disease
symptoms.

Fasudil Combined With BMSCs Affected
CD4+ T-Cell Proliferation and Induced the
Regulatory T-Cells in Vivo
Flow cytometry was performed to observe the effects of Fasudil,
BMSCs, or Fasudil combined with BMSCs on CD4+ T-cell
proliferation and the release of cytokines from T-cells. Splenic
MNCs from APP/PS1 Tg mice were isolated and expression of
CD25, IL-10, TGF-β and IFN-γ on CD4 T-cells were measured
by flow cytometry. All treatment groups were compared with the
NS control (Figure 3). In the double staining of CD4+/CD25+,
there was no statistically significant difference between Fasudiltreated, BMSCs-treated, or control mice; however, Fasudil
combined with BMSCs significantly increased CD4+/CD25+
(p < 0.05), suggesting that the combination therapy exhibits
more effective regulation of T-cells. Further, the role of IL-10,
TGF-β, and IFN-γ was examined by double staining of CD4+
and IL-10+, TGF-β+, or IFN-γ+, respectively. We observed
significantly decreased IL-10 (p < 0.05) and increased TGF-β
(p < 0.05) in CD4+ by Fasudil alone, and increased IL-10
(p < 0.01) and TGF-β (p < 0.05) in CD4+ by BMSCs
alone, but no change in IFN-γ by either treatment. In
contrast, expression of CD4+/IL-10+ (p < 0.001), CD4+/TGF-β+
(p < 0.001), CD4+/IFN-γ+ (p < 0.05) was significantly increased
by Fasudil combined with BMSCs, suggesting greater potency
of the combination treatment, which appears to prevent the
development of AD pathology and its progression by regulating
the CD4+ T-cell proliferation and cytokine release. Our study
provides evidence that Tregs can protect the development of AD
pathology and its progression. Systemic Tregs administration can
ameliorates disease progression and could be an effective AD
treatment (Baek et al., 2016).

DISCUSSION
We previously demonstrated that Fasudil reduced Aβ deposition
and ROCK-II expression in the brain of APP/PS1 Tg mice (Gu
and Zhang, 2017; Yu et al., 2017). In the present study, we
further showed that Fasudil or BMSCs used alone was effective to
decrease the severity of AD-related symptoms through peripheral
immune system responses, however, the combination of both
showed greater efficacy.
The main symptom of AD is cognition deficit, which is
considered to be caused by excessive formation of Aβ-protein
(Selkoe, 1999). One of the most promising approaches toward
the Aβ clearance is the use of immunotherapies (Jesudason
et al., 2007). Although brain pathology and relative changes
have been well studied, their impact on inflammatory processes
in the peripheral immune system, including the spleen, have
not been investigated (Subramanian et al., 2010). Abnormal
activation of ROCK has been found in animal models of AD.
ROCK activation increases the production of Aβ in the brain.
Therefore, we hypothesized that ROCK-II was a potential drug
target for the treatment of AD. Recent studies have shown
that ROCK-II inhibitors protect neurons by inhibiting caspase-3
(Xiao, 2008), leading to increases in the number of axons
in hippocampal neurons. Inhibition of ROCK-II also reduces
Aβ1–42 levels in the nervous system (Aleksis et al., 2017). In
the MWM test, improvement in spatial learning of APP/PS1 Tg
mice was observed following treatment with Fasudil or Fasudil

Fasudil Combined With BMSCs Shift
Macrophages to M2 Phenotype of CD11b
and Enhancement the Anti-inflammation
We also used flow cytometry to characterize the phenotype of
macrophages (M1 and M2 type) after treatment with Fasudil,
BMSCs, or Fasudil combined with BMSCs. Macrophages
were isolated from splenic MNCs in APP/PS1 Tg mice.
Macrophage M2 markers (CD11b+/IL-10+, CD11b+/CD206+),
M1 markers (CD11b+/MHC-II+, CD11b+/CD86+), and
phagocytic macrophage marker (CD11b+/CD16/32+) were
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combined with BMSCs; the combination therapy was even
more effective. BMSCs, which are not ROCK-II inhibitors,
potentiated the effect of Fasudil, a ROCK-II inhibitor, in terms
of reduction of ROCK-II expression. This is probably due to the
immunoregulatory ability of BMSCs. Decreased expression of
ROCK-II in the spleen produced by the combination of Fasudil
and BMSCs appears to be associated with enhanced immunity
in the brain, or at least resulted from bidirectional immunity
communication between the brain and spleen. A cascade of event
will follow to reduce Aβ or reduce the phosphorylation of tau.
In the peripheral immune system, Fasudil combined with
BMSCs significantly increased CD4 T-cell proliferation and
cytokine release and regulated the immune system to work
functionally. TGF-β1 has been shown to suppress glial and
T-cell mediated neuroinflammation; its inhibitory effect on Aβ
neurotoxicity has been considered as a potential therapeutic
approach in AD patients (Chen et al., 2015). This phenomenon
appears to be linked to a switch mechanism from a Th1 effector
to an IL-10-mediated regulatory response (Loewenbrueck et al.,
2010); release of IFN-γ from infiltrating Th1 cells accelerates
markers of disease in an animal model of AD (Browne et al.,
2013). Tregs have an impact on cognitive function. Inflammatory
conditions defined as excessive activation of immune cells
and release of cytokines, are associated with bidirectional
immune system-brain communication (Rosas-Ballina et al.,
2015). The cytokines of T-cell production have the ability to
increase macrophage phagocytosis. Cytokine production is a key
pathologic event in pro-inflammatory and anti-inflammatory
responses in AD (Gu and Zhang, 2017).
We further explored the role of the immune system and
the possible mechanism involved. It was found that Fasudil
combined with BMSCs switched M1 (MHC-II, CD86; RosasBallina et al., 2015) to M2 (IL-10, CD206; Rosas-Ballina
et al., 2015) phenotype of CD11b, significantly increasing
anti-inflammatory cytokines and enhancing the phagocytic
ability of macrophages (CD 16/32; Makarenkova et al., 2006).
Our data showed a trend of increased CD86 and MHC
(M1 markers), but it was not statistically significant, indicating
a major effect on M2, instead of M1, which may be caused
by the transformation from M1 to M2; leading to increased
production of the M2 regulatory cytokine IL-10 (Bispo da
Silva et al., 2017). We observed decreased IL-10 and increased
CD206 expression after Fasudil treatment. In contrast, both were
significantly increased by the combination treatment, suggesting
the progression of the disease. AD is a chronic disease and
inflammation forms gradually. Our results revealed that the
resting phase of M1 (pro-inflammatory) started to be activated
as indicated by increased pro-inflammatory factors, and then
turned into M2 phenotype exhibiting anti-inflammation, as
shown by increased CD206, an M2 marker. Tregs are regulators

that increase the ability of macrophages to devour inflammation.
T lymphocytes have to pass through two main barriers: the
blood-cerebrospinal fluid barrier (BCSFB) and the blood brain
barrier (BBB). In our previous studies, we have demonstrated
the protective effects of Fasudil on BBB function in EAE
mice. Fasudil may produce inhibition of the down-regulation of
Occludin and Zo-1 in the brain, indicating that Fasudil maintains
the integrity of BBB (Gu et al., 2017). All types of peripheral
immune cells may infiltrate through the pathologically altered
BBB during AD pathogenesis (Mietelska-Porowska and Wojda,
2017).
In summary, our study demonstrated that Fasudil, a ROCK-II
inhibitor, alone or in combination with BMSCs, improved
cognitive function of APP/PS1 Tg mice through the regulation of
the peripheral immune system, including decreased expression of
ROCK-II, induction of Tregs, switching pro-inflammatory M1 to
anti-inflammatory M2 phenotype, and increasing phagocytic
macrophages in the spleen. The immunological reaction in
the CNS was decreased through inhibition of the peripheral
immunity after treatment with Fasudil in combination of
BMSCs, leading to improvement of CNS microenvironment and
promoting cognitive function. Further studies are required for
the detailed mechanisms of interaction of immunity between the
CNS and the peripheral immune system.

REFERENCES

Baas, M., Besancon, A., Goncalves, T., Valette, F., Yagita, H., Sawitzki, B.,
et al. (2016). TGFβ-dependent expression of PD-1 and PD-L1 controls
CD8+ T cell anergy in transplant tolerance. Elife 5:e08133. doi: 10.7554/elife.
08133
Baek, H., Ye, M., Kang, G. H., Lee, C., Lee, G., Choi, D. B., et al.
(2016). Neuroprotective effects of CD4+ CD25+ Foxp3+ regulatory T cells

AUTHOR CONTRIBUTIONS
JY and YY designed the study, carried out the mouse behavioral
tests, immunoassays and flow cytometry. C-GM and YJ
conceived the study, participated in its design and coordination
and helped draft the manuscript. B-GX, H-TZ, G-XZ, GK and
JC participated in its design and revised the manuscript. H-TZ
revised and finalized the manuscript. QG, YZ and HY performed
the immunoassays and flow cytometry experiments. CL, YG and
ZC participated in the statistical analysis. All authors read and
approved the final manuscript.

FUNDING
This work was supported by research grants from the National
Natural Science Foundation of China (No. 81272163 to
C-GM, 81471412 to JY, and 81371414 to C-GM), the
Department of Science and Technology, Shanxi Province of
China (2016ZD0505 to JY), Datong Municipal Science and
Technology Bureau (2017134 to YY, 2017136 to QG), PhD
Initiation Grant of Datong University (2016-B-01 to YY),
and the Open Project of State Key Laboratory of Molecular
Developmental Biology, Institute of Genetics and Developmental
Biology, Chinese Academy of Sciences, Beijing, China (2018MDB-KF-07 to YY).

Aleksis, R., Oleskovs, F., Jaudzems, K., Pahnke, J., and Biverstal, H. (2017).
Structural studies of amyloid-β peptides: unlocking the mechanism of
aggregation and the associated toxicity. Biochimie 140, 176–192. doi: 10.1016/j.
biochi.2017.07.011

Frontiers in Aging Neuroscience | www.frontiersin.org

8

July 2018 | Volume 10 | Article 216

Yu et al.

Fasudil Attenuates Alzheimer’s Disease Symptoms

in a 3xTg-AD Alzheimer’s disease model. Oncotarget 7, 69347–69357.
doi: 10.18632/oncotarget.12469
Bispo da Silva, A., Cerqueira Coelho, P. L., Alves Oliveira Amparo, J., Alves de
Almeida Carneiro, M. M., Pereira Borges, J. M., Dos Santos Souza, C., et al.
(2017). The flavonoid rutin modulates microglial/macrophage activation to a
CD150/CD206 M2 phenotype. Chem. Biol. Interact. 274, 89–99. doi: 10.1016/j.
cbi.2017.07.004
Browne, T. C., McQuillan, K., McManus, R. M., O’Reilly, J. A., Mills, K. H.,
and Lynch, M. A. (2013). IFN-γ Production by amyloid β-specific Th1 cells
promotes microglial activation and increases plaque burden in a mouse model
of Alzheimer’s disease. J. Immunol. 190, 2241–2251. doi: 10.4049/jimmunol.
1200947
Cai, C., Wu, Q., Luo, Y., Ma, H., Shen, J., Zhang, Y., et al. (2017). In silico
prediction of ROCK II inhibitors by different classification approaches. Mol.
Divers. 21, 791–807. doi: 10.1007/s11030-017-9772-5
Chen, J. H., Ke, K. F., Lu, J. H., Qiu, Y. H., and Peng, Y. P. (2015).
Protection of TGF-β1 against neuroinflammation and neurodegeneration
in Aβ1–42-induced Alzheimer’s disease model rats. PLoS One 10:e0116549.
doi: 10.1371/journal.pone.0116549
Eftekharzadeh, M., Nobakht, M., Alizadeh, A., Soleimani, M., Hajghasem, M.,
Kordestani Shargh, B., et al. (2015). The effect of intrathecal delivery of bone
marrow stromal cells on hippocampal neurons in rat model of Alzheimer’s
disease. Iran. J. Basic Med. Sci. 18, 520–525.
Gu, Q.-F., Yu, J.-Z., Wu, H., Li, Y.-H., Fan, H.-J., Chai, Z., et al. (2017). Effect of
FSD-C10 on modulation of inflammatory microenvironment in an Alzheimer
disease double transgenic mouse model. Chin. J. Pathophysiol. 33, 1729–1737.
Gu, Q.-F., and Zhang, H. (2017). Research about Protective effects of Fasudil
on BBB function in EAE mice and study of the mechanisms. Chin.
J. Neuroimmunol. Neurol. 24, 99–104.
Hou, S. W., Liu, C. Y., Li, Y. H., Yu, J. Z., Feng, L., Liu, Y. T., et al.
(2012). Fasudil ameliorates disease progression in experimental autoimmune
encephalomyelitis, acting possibly through antiinflammatory effect. CNS
Neurosci. Ther. 18, 909–917. doi: 10.1111/cns.12002
Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A.,
et al. (2004). Mutant presenilins specifically elevate the levels of the 42 residue
β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ
secretase. Hum. Mol. Genet. 13, 159–170. doi: 10.1093/hmg/ddh019
Jesudason, E. P., Baben, B., Ashok, B. S., Masilamoni, J. G., Kirubagaran, R.,
Jebaraj, W. C., et al. (2007). Anti-inflammatory effect of melatonin on Aβ
vaccination in mice. Mol. Cell. Biochem. 298, 69–81. doi: 10.1007/s11010-0069353-x
Li, X. Y., Men, W. W., Zhu, H., Lei, J. F., Zuo, F. X., Wang, Z. J., et al.
(2016). Age- and brain region-specific changes of glucose metabolic disorder,
learning, and memory dysfunction in early Alzheimer’s disease assessed in
APP/PS1 transgenic mice using 18 F-FDG-PET. Int. J. Mol. Sci. 17:E1707.
doi: 10.3390/ijms17101707
Loewenbrueck, K. F., Tigno-Aranjuez, J. T., Boehm, B. O., Lehmann, P. V., and
Tary-Lehmann, M. (2010). Th1 responses to β-amyloid in young humans
convert to regulatory IL-10 responses in Down syndrome and Alzheimer’s
disease. Neurobiol. Aging 31, 1732–1742. doi: 10.1016/j.neurobiolaging.2008.
09.007
Makarenkova, V. P., Bansal, V., Matta, B. M., Perez, L. A., and Ochoa, J. B.
(2006). CD11b+ /Gr-1+ myeloid suppressor cells cause T cell dysfunction after
traumatic stress. J. Immunol. 176, 2085–2094. doi: 10.4049/jimmunol.176.4.
2085
Mietelska-Porowska, A., and Wojda, U. (2017). T lymphocytes and inflammatory
mediators in the interplay between brain and blood in Alzheimer’s
disease: potential pools of new biomarkers. J. Immunol. Res. 2017:4626540.
doi: 10.1155/2017/4626540
Mueller, B. K., Mack, H., and Teusch, N. (2005). Rho kinase, a promising
drug target for neurological disorders. Nat. Rev. Drug Discov. 4, 387–398.
doi: 10.1038/nrd1719
Prince, M., Comas-Herrera, A., Adelina, K., Martin, G., Guerchet, M., and
Karagiannidou, M. (2016). World Alzheimer Report 2016: Improving Healthcare
for People Living with Dementia: Coverage, Quality and Costs Now and in the
Future. London, UK: Alzheimer’s Disease International.

Frontiers in Aging Neuroscience | www.frontiersin.org

Rosas-Ballina, M., Valdes-Ferrer, S. I., Dancho, M. E., Ochani, M., Katz, D.,
Cheng, K. F., et al. (2015). Xanomeline suppresses excessive pro-inflammatory
cytokine responses through neural signal-mediated pathways and improves
survival in lethal inflammation. Brain Behav. Immun. 44, 19–27. doi: 10.1016/j.
bbi.2014.07.010
Selkoe, D. J. (1999). Translating cell biology into therapeutic advances in
Alzheimer’s disease. Nature 399, A23–A31. doi: 10.1038/399a023
Sil, S., Ghosh, A., and Ghosh, T. (2016). Impairment of blood brain barrier
is related with the neuroinflammation induced peripheral immune status in
intracerebroventricular colchicine injected rats: an experimental study with
mannitol. Brain Res. 1646, 278–286. doi: 10.1016/j.brainres.2016.05.052
Song, G. J., and Suk, K. (2017). Pharmacological modulation of functional
phenotypes of microglia in neurodegenerative diseases. Front. Aging Neurosci.
9:139. doi: 10.3389/fnagi.2017.00139
Subramanian, S., Ayala, P., Wadsworth, T. L., Harris, C. J., Vandenbark, A. A.,
Quinn, J. F., et al. (2010). CCR6: a biomarker for Alzheimer’s-like disease
in a triple transgenic mouse model. J. Alzheimers Dis. 22, 619–629.
doi: 10.3233/JAD-2010-100852
Torres, K. C., Araújo Pereira, P., Lima, G. S., Bozzi, I. C., Rezende, V. B.,
Bicalho, M. A., et al. (2013). Increased frequency of T cells expressing
IL-10 in Alzheimer disease but not in late-onset depression patients. Prog.
Neuropsychopharmacol. Biol. Psychiatry 47, 40–45. doi: 10.1016/j.pnpbp.2013.
07.021
Wada, N., Bartold, P. M., and Gronthos, S. (2011). Human foreskin fibroblasts
exert immunomodulatory properties by a different mechanism to bone marrow
stromal/stem cells. Stem Cells Dev. 20, 647–659. doi: 10.1089/scd.2010.0246
Wen, X., Wang, L., Liu, Z., Liu, Y., and Hu, J. (2014). Intracranial injection of
PEG-PEI/ROCK II-siRNA improves cognitive impairment in a mouse model
of Alzheimer’s disease. Int. J. Neurosci. 124, 697–703. doi: 10.3109/00207454.
2013.877014
Wu, Q. Y., Li, J., Feng, Z. T., and Wang, T. H. (2007). Bone marrow stromal cells
of transgenic mice can improve the cognitive ability of an Alzheimer’s disease
rat model. Neurosci. Lett. 417, 281–285. doi: 10.1016/j.neulet.2007.02.092
Xiao, B.-G. (2008). The research status of Rho kinase inhibitor and its application
prospect in nervous system disease. J. Chongqing Med. University 33:2.
Xin, Y. L., Yu, J. Z., Yang, X. W., Liu, C. Y., Li, Y. H., Feng, L., et al. (2015). FSDC10: a more promising novel ROCK inhibitor than Fasudil for treatment of
CNS autoimmunity. Biosci. Rep. 35:e00247. doi: 10.1042/BSR20150032
Yang, J., Yan, Y., Ciric, B., Yu, S., Guan, Y., Xu, H., et al. (2010). Evaluation of
bone marrow- and brain-derived neural stem cells in therapy of central nervous
system autoimmunity. Am. J. Pathol. 177, 1989–2001. doi: 10.2353/ajpath.2010.
091203
Yu, J. Z., Ding, J., Ma, C. G., Sun, C. H., Sun, Y. F., Lu, C. Z., et al.
(2010). Therapeutic potential of experimental autoimmune encephalomyelitis
by Fasudil, a Rho kinase inhibitor. J. Neurosci. Res. 88, 1664–1672.
doi: 10.1002/jnr.22339
Yu, J. Z., Li, Y. H., Liu, C. Y., Wang, Q., Gu, Q. F., Wang, H. Q.,
et al. (2017). Multitarget therapeutic effect of fasudil in
APP/PS1transgenic mice. CNS Neurol. Disord. Drug Targets 16, 199–209.
doi: 10.2174/1871527315666160711104719
Zhao, Y., Zhang, Q., Xi, J., Xiao, B., Li, Y., and Ma, C. (2015). Neuroprotective
effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin
dependent pathways in a mice model of Parkinson’s disease. Int. J. Clin. Exp.
Pathol. 8, 2354–2364.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Yu, Yan, Gu, Kumar, Yu, Zhao, Liu, Gao, Chai, Chumber, Xiao,
Zhang, Zhang, Jiang and Ma. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.

9

July 2018 | Volume 10 | Article 216

